Back to Newsroom

Fibrocell Science Chairman & CEO David Pernock Joins Board of Alliance for Regenerative Medicine

EXTON, Pa.–(BUSINESS WIRE)– Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for skin diseases and conditions with high unmet medical needs, today announced Chairman and CEO David Pernock has joined the board of the Alliance for Regenerative Medicine (ARM), a global advocacy organization whose diverse membership represents leading regenerative medicine companies and investors, university-based and non-profit research institutions, patient advocacy groups, pharmaceutical companies engaged in regenerative medicine research, and other organizations supporting regenerative medicine.